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Introduction
In 1992, the World Health Organization recom-
mended that all countries should have universal infant
and/or adolescent hepatitis B vaccination program.1
Routine hepatitis B vaccination program for newborns
was introduced into our national vaccination program
in 1998. Hepatitis B vaccines are prepared from highly
purified hepatitis B virus surface antigen (HBsAg).
Minor side effects such as local pain, fever, asthenia,
polymyalgia, headache, and chronic fatigue syndrome
are frequently reported. The hepatitis B vaccine has
been linked to immunological and neurological disor-
ders, including rheumatoid arthritis, multiple sclerosis,
Guillain-Barré syndrome, encephalomyelitis, diabetes,
and optic neuritis.2–9 Optic neuritis is defined as inflam-
mation of the optic nerve. Pain and temporary vision
loss are common symptoms of optic neuritis. The most
frequent cause of optic neuritis is multiple sclerosis;
other reasons include viral and bacterial infections and
medical reactions. Optic neuritis may develop after
hepatitis B vaccination.7–10
The mechanism of retrobulbar optic neuritis is
uncertain, but autoimmune inflammation has been
suggested.11,12 Treatment with systemic steroids leads
to regression of inflammation in the optic nerve. Only
a few pediatric cases of optic neuritis as a complication
after hepatitis B vaccination have been reported in the
medical literature so far. Here, we report a case of this
rare possible complication of hepatitis B immunization.
Case Report
A previously healthy 9-year-old girl was referred to
our hospital with decrease in vision and pain in the left
eye 1 week after hepatitis B vaccination. Systematic
physical and neurological examinations were unremark-
able. Fundus examination revealed optic disc edema
and parapapillary hemorrhage. Visual acuity was estab-
lished as 4/10 (Figure 1). A diagnosis of optic neuritis
was considered. The patient did not have a history of
lead exposure, and had not previously received radio-
therapy or used any other agents that could have caused
optic neuritis such as ethambutol, isoniazid, chloram-
phenicol, or vincristine.
Serological tests for the following were negative:
Treponema pallidum agglutination reaction test,
human immunodeficiency virus antibodies (anti-HIV:
0.20 S/CO), cytomegalovirus antibodies (anti-CMV),
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hepatitis B surface antigen (HbsAg: 0.46 S/CO), IgM
antibody to hepatitis B core antigen (anti-HBc IgM:
0.06 S/CO), IgM antibody to hepatitis A virus (anti-
HAV IgM: 0.16 S/CO) and hepatitis C virus anti-
bodies (anti-HCV: 0.21 S/CO). Hepatitis B surface
antibody (anti-HBs) was positive: > 100 mIU/mL.
Antinuclear antibody (ANA: 1:20) and anti-double
stranded DNA antibody (anti-dsDNA < 10 IU/mL)
titers were negative.
Hematological and biochemical parameters were
within normal limits. Examination of a cerebrospinal
fluid (CSF) sample for presence of white blood cells,
red blood cells, protein content, and glucose level was
normal. Blood, CSF and tuberculosis cultures were
negative. Computed tomography and magnetic reso-
nance imaging of the brain were normal. We identified
the differential diagnoses as multiple sclerosis, intracra-
nial tumors, obstructive hydrocephaly, intracranial
hemorrhage, edema secondary to trauma, meningoen-
cephalitis, and toxic encephalopathy.
A diagnosis of vaccine-induced optic neuritis was
made. The patient was treated with pulsed-dose steroid
(30 mg/kg/day) for 4 days. Results of the visual acu-
ity evaluation performed during these 4 days of treat-
ment were 4/10, 7/10, 9/10 and 10/10, respectively.
Visual acuity improved after 2 weeks of systemic cor-
ticosteroid treatment. We observed total recovery in
the long-term follow-up (Figure 2).
Discussion
A vaccine against hepatitis B virus first became avail-
able in the United States in 1982. Hepatitis B vaccina-
tion has a key role in the control of hepatitis B. Mass
hepatitis B vaccination in children decreases the car-
riage of the virus and thus prevents the serious conse-
quences of hepatitis B virus infection, including liver
cancer and cirrhosis.2 A study in Taiwan showed that
6–10 years after the initiation of the hepatitis B mass-
vaccination program, the incidence of childhood hepa-
tocellular carcinoma had declined significantly.3
Several local and systemic side effects such as myal-
gia, fatigue, transient fever, headache, dizziness, nausea,
and vomiting, can be observed within 24–48 hours fol-
lowing hepatitis B vaccination. Serious adverse effects
reported after receiving hepatitis B vaccine are very
uncommon.4,6–8 Although many serious effects are
claimed to be associated with hepatitis B vaccination, a
causal association between hepatitis B vaccination and
chronic fatigue syndrome, arthritis, diabetes and
autoimmune disorders has not been established. The
majority of ophthalmological complications following
vaccination consists of vision loss, optic neuritis, papil-
lary edema, uveitis, acute placoid pigment epitheliopa-
thy, and central vein occlusion.9–11 Most of these side
effects might be related to immune complexes. Three
mechanisms—molecular mimicry, bystander activation,
and superantigen stimulation—may play roles in the
development of demyelinating diseases of the central
and peripheral nervous systems.12,13 Vaccination could
enhance the risk of autoimmunity in genetically-
susceptible individuals.13 Shaw et al evaluated neuro-
logical events associated with hepatitis B vaccination.
They investigated 850,000 individuals who received the
plasma-derived hepatitis B vaccine. They found 10 cases
of Bell’s palsy, 9 cases of Guillain-Barré syndrome, 5
cases of lumbar radiculopathy, 3 cases of brachial plexus
neuropathy, 5 cases of optic neuritis, and 4 cases of
transverse myelitis.14 Plasma-derived hepatitis B vaccine
Figure 2. Improvement in optic disc edema following treatment.Figure 1. Optic disc with bilateral edema.
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is not produced in the United States, but such vaccines
are still being produced in other countries.
Recombinant hepatitis B vaccine may also induce
serious side effects, including autoimmune diseases, vas-
culitis, demyelinating neurological diseases and oph-
thalmological diseases.3–9
Geier and Geier searched the Vaccine Adverse Event
Reporting System (VAERS) database and the scien-
tific literature for adverse events following hepatitis B
vaccination.15 They found that post-vaccination serious
adverse effects were primarily observed among adult
hepatitis B vaccine recipients, with a female/male ratio
of 2.2, and within a few days to weeks following immu-
nization (Table 1). Our patient was female but younger
(9 years old) than the patients evaluated by Geier and
Geier. She presented to our hospital with decrease in
vision and pain in the left eye a week after hepatitis B
vaccination; the onset of clinical manifestations was sim-
ilar with the median onset reported in this large study.
We reviewed all available scientific and medical data
about ophthalmological complications after hepatitis
B vaccination in children; only a few pediatric cases of
optic neuritis as a complication of hepatitis B vaccina-
tion have been reported. Mikaeloff et al16 evaluated the
risk of acute central nervous system (CNS) inflamma-
tory demyelination in childhood after hepatitis B vac-
cination. The mean age of the 349 cases included in
the study was 9.3 ± 4.6 years; isolated optic neuritis
was reported in 19 (9.6%) cases with a single episode
of acute CNS inflammatory demyelination without
relapse. This population-based case-control study
reported that hepatitis B vaccine did not increase the
risk of CNS inflammatory demyelination in child-
hood within a risk period of ≥ 3 years or considering
the number of injections. Roussat et al analyzed the
Table 1. Summary of cases with optic neuritis following hepatitis
B vaccination
Optic neuritis 
Median Median 
after hepatitis Cases (n)
age (yr) onset (d)
B vaccine
Reported in 4 43 7
the scientific 
literature15
Reported in 96 33 13
the VAERS 
database15
Mikaeloff 19 9.3 ± 4.6* Not specified
et al16
Roussat 2 10.7 Not specified
et al17
*Mean ± standard deviation.
clinical features and treatment of acute optic neuritis
in children; they found only 2 cases after hepatitis B
vaccination.17 The mean age of patients was 10.7 years.
They reported that healing was accelerated with high-
dose steroid treatment. We applied pulsed-dose steroid
for 4 days at a dose of 30 mg/kg/day in our 9-year-old
patient, and observed significant improvements in the
visual acuity evaluations performed during treatment.
Structural changes of the disc (pseudopapillary
edema, pseudoneuritis), hypertension, diabetes melli-
tus, bacterial and viral infections, intracranial tumors,
cerebral edema secondary to trauma, meningoen-
cephalitis, and some metabolic diseases should also be
considered in the differential diagnoses of optic disc
edema. In children, optic neuritis can be seen in con-
junction with neuromyelitis optica (Devic’s disease).
This syndrome presents with rapid and severe bilateral
vision loss, transverse myelitis, and paraplegia. Optic
neuritis can also develop secondary to an exogenous
toxin or medicine. Our patient did not have a history
of drug use or exposure to toxic agents. No causes
other than vaccination were found.
In conclusion, hepatitis B vaccine is safe and effec-
tive and can be used in newborns. Optic neuritis is a
very rare complication of hepatitis B vaccination in
childhood. Parents should be aware of the potential
serious side effects of the vaccine. Since the vaccina-
tion provides protection against hepatitis B and its
severe long-term complications, the risks of the vac-
cine are outweighed by the prophylactic benefits of
vaccination. We conclude that the present universal
hepatitis B vaccination program to eradicate hepatitis
B should be continued.
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